- Home
- LGCL vs VYNE Comparison
LGCL vs VYNE Comparison
Compare LGCL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- VYNE
- Stock Information
- Founded
- LGCL 2009
- VYNE 2003
- Country
- LGCL China
- VYNE United States
- Employees
- LGCL N/A
- VYNE N/A
- Industry
- LGCL
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- VYNE Health Care
- Exchange
- LGCL NYSE
- VYNE Nasdaq
- Market Cap
- LGCL 43.2M
- VYNE 35.7M
- IPO Year
- LGCL 2024
- VYNE 2018
- Fundamental
- Price
- LGCL $0.48
- VYNE $1.64
- Analyst Decision
- LGCL
- VYNE Strong Buy
- Analyst Count
- LGCL 0
- VYNE 2
- Target Price
- LGCL N/A
- VYNE $6.88
- AVG Volume (30 Days)
- LGCL 183.9K
- VYNE 199.7K
- Earning Date
- LGCL 11-22-2024
- VYNE 03-06-2025
- Dividend Yield
- LGCL N/A
- VYNE N/A
- EPS Growth
- LGCL 11.49
- VYNE N/A
- EPS
- LGCL 0.07
- VYNE N/A
- Revenue
- LGCL $145,690,427.00
- VYNE $501,000.00
- Revenue This Year
- LGCL N/A
- VYNE N/A
- Revenue Next Year
- LGCL N/A
- VYNE $20.00
- P/E Ratio
- LGCL $6.42
- VYNE N/A
- Revenue Growth
- LGCL N/A
- VYNE 18.16
- 52 Week Low
- LGCL $0.41
- VYNE $1.53
- 52 Week High
- LGCL $3.76
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- VYNE 34.09
- Support Level
- LGCL N/A
- VYNE $1.53
- Resistance Level
- LGCL N/A
- VYNE $1.86
- Average True Range (ATR)
- LGCL 0.00
- VYNE 0.16
- MACD
- LGCL 0.00
- VYNE 0.00
- Stochastic Oscillator
- LGCL 0.00
- VYNE 24.44
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.